Literature DB >> 20047995

Tumorigenicity of the miR-17-92 cluster distilled.

Gijs van Haaften1, Reuven Agami.   

Abstract

The miR-17-92 gene cluster, with its six different mature microRNAs (miRNAs), has an established oncogenic function. However, the oncogenic contribution of each individual miRNA in the cluster has not been assigned. Two studies published in the December 15, 2009, issue of Genes & Development by Mu and colleagues (pp. 2806-2811) and Olive and colleagues (pp. 2839-2849) dissected the miR-17-92 cluster to its individual miRNA components and identified their relative contributions to oncogenic transformation in mouse model systems.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20047995      PMCID: PMC2802185          DOI: 10.1101/gad.1887110

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  35 in total

1.  A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy.

Authors:  Clemens A Schmitt; Jordan S Fridman; Meng Yang; Soyoung Lee; Eugene Baranov; Robert M Hoffman; Scott W Lowe
Journal:  Cell       Date:  2002-05-03       Impact factor: 41.582

2.  A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation.

Authors:  Yoji Hayashita; Hirotaka Osada; Yoshio Tatematsu; Hideki Yamada; Kiyoshi Yanagisawa; Shuta Tomida; Yasushi Yatabe; Katsunobu Kawahara; Yoshitaka Sekido; Takashi Takahashi
Journal:  Cancer Res       Date:  2005-11-01       Impact factor: 12.701

3.  c-Myc-regulated microRNAs modulate E2F1 expression.

Authors:  Kathryn A O'Donnell; Erik A Wentzel; Karen I Zeller; Chi V Dang; Joshua T Mendell
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

4.  A microRNA polycistron as a potential human oncogene.

Authors:  Lin He; J Michael Thomson; Michael T Hemann; Eva Hernando-Monge; David Mu; Summer Goodson; Scott Powers; Carlos Cordon-Cardo; Scott W Lowe; Gregory J Hannon; Scott M Hammond
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

5.  miR-19 is a key oncogenic component of mir-17-92.

Authors:  Virginie Olive; Margaux J Bennett; James C Walker; Cong Ma; Iris Jiang; Carlos Cordon-Cardo; Qi-Jing Li; Scott W Lowe; Gregory J Hannon; Lin He
Journal:  Genes Dev       Date:  2009-12-15       Impact factor: 11.361

6.  Bim is a suppressor of Myc-induced mouse B cell leukemia.

Authors:  Alexander Egle; Alan W Harris; Philippe Bouillet; Suzanne Cory
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-12       Impact factor: 11.205

7.  The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice.

Authors:  J M Adams; A W Harris; C A Pinkert; L M Corcoran; W S Alexander; S Cory; R D Palmiter; R L Brinster
Journal:  Nature       Date:  1985 Dec 12-18       Impact factor: 49.962

8.  Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma.

Authors:  Akinobu Ota; Hiroyuki Tagawa; Sivasundaram Karnan; Shinobu Tsuzuki; Abraham Karpas; Shigeki Kira; Yasuko Yoshida; Masao Seto
Journal:  Cancer Res       Date:  2004-05-01       Impact factor: 12.701

9.  An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo.

Authors:  Michael T Hemann; Jordan S Fridman; Jack T Zilfou; Eva Hernando; Patrick J Paddison; Carlos Cordon-Cardo; Gregory J Hannon; Scott W Lowe
Journal:  Nat Genet       Date:  2003-02-03       Impact factor: 38.330

10.  Prediction of mammalian microRNA targets.

Authors:  Benjamin P Lewis; I-hung Shih; Matthew W Jones-Rhoades; David P Bartel; Christopher B Burge
Journal:  Cell       Date:  2003-12-26       Impact factor: 41.582

View more
  41 in total

Review 1.  Cancer epigenetics: above and beyond.

Authors:  Mariana Brait; David Sidransky
Journal:  Toxicol Mech Methods       Date:  2011-05       Impact factor: 2.987

Review 2.  Mechanisms of epigenetic deregulation in lymphoid neoplasms.

Authors:  Yanwen Jiang; Katerina Hatzi; Rita Shaknovich
Journal:  Blood       Date:  2013-05-23       Impact factor: 22.113

3.  BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells.

Authors:  Z Xu; P P Sharp; Y Yao; D Segal; C H Ang; S L Khaw; B J Aubrey; J Gong; G L Kelly; M J Herold; A Strasser; A W Roberts; W S Alexander; C J Burns; D C S Huang; S P Glaser
Journal:  Leukemia       Date:  2016-03-08       Impact factor: 11.528

4.  MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies.

Authors:  Ronit Vogt Sionov
Journal:  ISRN Hematol       Date:  2013-01-29

Review 5.  Epigenetic Control of B Cell Development and B-Cell-Related Immune Disorders.

Authors:  Yan Bao; Xuetao Cao
Journal:  Clin Rev Allergy Immunol       Date:  2016-06       Impact factor: 8.667

6.  CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set.

Authors:  William C Reinhold; Margot Sunshine; Hongfang Liu; Sudhir Varma; Kurt W Kohn; Joel Morris; James Doroshow; Yves Pommier
Journal:  Cancer Res       Date:  2012-07-15       Impact factor: 12.701

Review 7.  Apoptotic cell signaling in cancer progression and therapy.

Authors:  Jessica Plati; Octavian Bucur; Roya Khosravi-Far
Journal:  Integr Biol (Camb)       Date:  2011-02-22       Impact factor: 2.192

8.  MicroRNA expression in mouse oligodendrocytes and regulation of proteolipid protein gene expression.

Authors:  Erming Wang; Franca Cambi
Journal:  J Neurosci Res       Date:  2012-04-14       Impact factor: 4.164

9.  Alterations of microRNAs throughout the malignant evolution of cutaneous squamous cell carcinoma: the role of miR-497 in epithelial to mesenchymal transition of keratinocytes.

Authors:  A Mizrahi; A Barzilai; D Gur-Wahnon; I Z Ben-Dov; S Glassberg; T Meningher; E Elharar; M Masalha; J Jacob-Hirsch; H Tabibian-Keissar; I Barshack; J Roszik; R Leibowitz-Amit; Y Sidi; D Avni
Journal:  Oncogene       Date:  2017-09-18       Impact factor: 9.867

10.  PGE2-driven expression of c-Myc and oncomiR-17-92 contributes to apoptosis resistance in NSCLC.

Authors:  Kostyantyn Krysan; Rebecca Kusko; Tristan Grogan; James O'Hearn; Karen L Reckamp; Tonya C Walser; Edward B Garon; Marc E Lenburg; Sherven Sharma; Avrum E Spira; David Elashoff; Steven M Dubinett
Journal:  Mol Cancer Res       Date:  2014-01-27       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.